Hypothalamic thyrotropin-releasing hormone (TRH) stimulates thyroid-stimulating hormone (TSH) secretion from the anterior pituitary. TSH then initiates thyroid hormone (TH) synthesis and release from the thyroid gland. While opposing TRH and TH inputs regulate the hypothalamic-pituitary-thyroid (HPT) axis, TH negative feedback is thought to be the primary regulator. This hypothesis, however, has yet to be proven in vivo. To elucidate the relative importance of TRH and TH in regulating the HPT axis, we have generated mice, which lack either TRH, the β isoforms of TH receptors (TRβ KO), or both (double KO). TRβ KO mice have significantly higher TH and TSH levels compared to wild-type mice, in contrast to double KO mice, which have reduced TH and TSH levels. Unexpectedly, hypothyroid double KO mice also failed to mount a significant rise in serum TSH levels, and pituitary TSH immunostaining was markedly reduced compared to all other hypothyroid mouse genotypes. This impaired TSH response, however, was not due to a reduced number of pituitary thyrotrophs because thyrotroph cell number, as assessed by counting TSH immunopositive cells, was restored after chronic TRH treatment. Thus, TRH is absolutely required for both TSH and TH synthesis but is not necessary for thyrotroph cell development.
Hypothalamic thyrotropin-releasing hormone (TRH) stimulates thyroid-stimulating hormone (TSH) secretion from the anterior pituitary. TSH then initiates thyroid hormone (TH) synthesis and release from the thyroid gland. While opposing TRH and TH inputs regulate the hypothalamic-pituitary-thyroid (HPT) axis, TH negative feedback is thought to be the primary regulator. This hypothesis, however, has yet to be proven in vivo. To elucidate the relative importance of TRH and TH in regulating the HPT axis, we have generated mice, which lack either TRH, the β isoforms of TH receptors (TRβ KO), or both (double KO). TRβ KO mice have significantly higher TH and TSH levels compared to wild-type mice, in contrast to double KO mice, which have reduced TH and TSH levels. Unexpectedly, hypothyroid double KO mice also failed to mount a significant rise in serum TSH levels, and pituitary TSH immunostaining was markedly reduced compared to all other hypothyroid mouse genotypes. This impaired TSH response, however, was not due to a reduced number of pituitary thyrotrophs because thyrotroph cell number, as assessed by counting TSH immunopositive cells, was restored after chronic TRH treatment. Thus, TRH is absolutely required for both TSH and TH synthesis but is not necessary for thyrotroph cell development.
Thyroid hormones (THs) thyroxine (T 4 )
and its biologically active derivative triiodothyronine (T 3 ) play a critical role in development, growth, and cellular metabolism. T 3 acts by binding to specific nuclear receptor proteins, which modify gene transcription. Free TH levels are regulated by negative feedback at the hypothalamic thyrotropin-releasing hormone (TRH) neuron and pituitary thyrotroph. The synthesis of TRH, produced in the hypothalamus, and the α and β subunits of thyrotropin (TSH, thyroid-stimulating hormone), produced in the anterior lobe of the pituitary, are inhibited at the transcriptional level by TH (1, 2) . TH also inhibits post-translational modification of TSH as well as TSH release (1) . Furthermore, TH also modulates TSH expression by altering pituitary levels of TRH receptors, and thyroid hormone receptors (TRs) (3, 4) . While hypothalamic TRH stimulates TSH synthesis and release, TH negative feedback at the pituitary is believed to be the most important physiological regulator of serum TSH levels (5) .
Thyroid hormones have both genomic and non-genomic effects (6, 7) , although most workers believe that thyroid hormones act predominantly through a genomic mechanism. Genomic action is mediated by different TR isoforms, which are members of the nuclear receptor superfamily of ligand modulated transcriptional factors (8) . Alternative splicing and alternative transcription 2 initiation of two genes produce all known ligandbinding TR isoforms: TRα1, TRβ1, TRβ2 and TRβ3. The expression and regulation of the TRs vary with isoform and tissue type. Whereas both TRα1 and TRβ1 are expressed in most cell types, TRβ2 mRNA is selectively expressed in the anterior pituitary, specific areas of the hypothalamus, and in the developing brain and middle ear (9) (10) (11) . Mice deficient in either TRα or TRβ display unique phenotypes, suggesting that different TR isoforms have unique regulatory roles (12) (13) (14) (15) (16) (17) (18) (19) (20) . TH effects on negative feedback of the hypothalamic-pituitarythyroid (HPT) axis are mediated, mostly, by the β2 isoform of TR (15, 16, (18) (19) (20) .
TRH is the major stimulator of TSH synthesis and release from the anterior pituitary (21, 22) .
Previous data have shown that TRH administration to dams stimulated fetal pituitary and thyroid function and that in vitro addition of TRH activated embryonic pituitary cells. These data suggested that TRH is involved in regulation of pituitary development and differentiation (23, 24) . In mice deficient in TRH (TRH KO mice), however, a different conclusion was reached. Histological examination of the embryonic anterior pituitary of these KO mice revealed that the number of TSH-β immunopositive cells was not affected in pups born to TRH deficient mothers (25) . Thus, neither embryonic nor maternal TRH is required for normal development of pituitary thyrotrophs. Adult animals lacking TRH have slightly increased levels of TSH and lower levels of thyroid hormones, suggesting a decrease in the bioactivity of TSH and central hypothyroidism (26) . To understand the relative importance of TRH and thyroid hormone feedback in regulation of the HPT axis, we studied TRH, TRβ and both TRH and TRβ KO mouse models.
Experimental Procedures

Generation of TRH and TR-β knockout (KO) mice.
TRH KO and complete TRβ KO mice were generated as described previously (26, 27 , double KO). Genotyping of TRH and TRβ gene KO animals was performed on tail extracts of genomic DNA, using Southern blot analysis and polymerase chain reaction (PCR) as described previously (26, 27) .
Animals were maintained under light/dark cycles of 12:12 hours (lights on at 0600 h), weaned after 21 days, and fed chow and water ad libitum. All mice used in these experiments were of the same mixed background strain (129svj/C57BL/6), and wild-type (WT) littermate mice served as normal controls. All animal experiments were performed according to the National Institute of Health (NIH) Guide for the care and use of Laboratory Animals, and the protocols were approved by the Institutional Animal Care and Use Committee at the University of Chicago.
Serum thyroid hormone and TSH measurements
Serum thyroid hormone levels (total T 3 and T 4 ) were measured by solid phase radioimmunoassay (Coat-A-Count, DPC). Mouse serum TSH levels were measured by a sensitive heterologous radioimmunoassay, as described previously (35) . Serum TSH bioactivity was determined by measuring cyclic adenosine monophosphate, (cAMP) levels in a Chinese hamster ovary cell line stably transfected with a human TSH receptor cDNA, as previously described (36, 37) . Serum was depleted of TSH by treatment of mice with 5 µg L-T 4 for 10 days and used as a blank in all assays (35) . Mouse serum TSH standard was produced by rendering WT mice hypothyroid as described (35) . Hypothyroid mouse serum was diluted in TSH depleted serum to generate the standard curve. The standard curve was linear over the entire concentration range, indicating a lack of an interfering substance. This serum was also, not contaminated with other pituitary glycoproteins present in pituitary extracts. The TSH standard had identical immunological and biological activity as serum TSH derived from congenitally hypothyroid Pax-8 KO mice (37) .
Thyroid hormone suppression was induced in animals at 8 weeks of age with a low iodine diet (LoI) containing 0.15% 5-propyl-2-thiouracil, (PTU, Harlan Teklad Co., Madison, Wisconsin, USA) and 0.05% methimazole (MMI, Sigma-Aldrich, St. Louis, Missouri, USA) in water. After 5 weeks, animals received daily subcutaneous injections of either vehicle or L-T 3 (Sigma Corp) at a low (0.2 µg/100g body weight/day), medium (0.5 µ g/100g body weight/day), or high (1.0 µg/100g body weight/day) dose for 7 days each. The LoI/PTU diet and MMI in water were given throughout the L-T 3 treatment period. Animals were sacrificed 24 hours after the last injection of L-T 3 . A group of animals was also sacrificed after LoI/PTU diet, and these pituitaries subjected immunohistochemistry as described below.
TRH Treatment
Animals were given a LoI/PTU diet and MMI in water for a total of 24 days to induce hypothyroidism. After 14 days of LoI/PTU and MMI treatment, placebo pellets or pellets containing 10 mg of TRH (Innovative Research of America) were implanted subcutaneously. Blood samples were collected from the orbital vein 0, 5, and 10 days after pellet implantation, and TSH assayed as described above. Animals were sacrificed and pituitary glands subjected to immunohistochemistry as described below.
RNA analysis
Total RNA was extracted by standard methodology (TRIzol Reagent, Life Technologies, Invitrogen). For quantitative real-time reverse transcriptase PCR (real-time RT-PCR) analysis, reverse transcription (RT) was carried out on 2 µg of total pituitary RNA. Real-time RT-PCR analyses were performed in a fluorescent temperature cycler (MyiQ, single color Real-time PCR Detection System, Bio-Rad Laboratories) according to the recommendations of the manufacturer. Briefly, after initial denaturation at 50 o C for 2 min and 95 o C for 10 min, reactions were cycled 40 times using the following parameters for all genes studied: 95 o C for 15 seconds, 60 o C for 30 seconds, and 72 o C for 30 seconds. SYBR Green I (Bio-Rad) fluorescence was detected at the end of each cycle to monitor the amount of PCR product formed during that cycle. Primers used for the amplification of cDNAs of interest were synthesized by IDT (Integrated DNA Technologies). The sequence of the forward and reverse primers was, respectively: 5'-GTGTATGGGCTGTTGCTTCTCC-3' and 5'-GCACTCCGTATGATTCTCCACTCTG-3' for the TSH α-subunit, 5'-TCTCGCCGTCCTCCTCTC CGTGCTT-3' and 5'-AGTTGGTTCTGACAGC CTCGTG-3' for the TSH β -subunit, 5'-TTCTCTCCTTCCTCCCATCCTTT-3' and 5'-GGCTGGAGGGTCTGAGGG-3' for TRα1 and 5'-CGGCTACCACATCCAAGGAA-3' and 5'-GCTGGAATTACCGCGGCT-3' for the 18S ribosomal subunit.
Relative mRNA levels (2Δ Ct) were determined by comparing the PCR cycle threshold (Ct) between groups. The purity of the PCR products was checked by analyzing the melting curves. Each sample was measured in duplicate and each experiment was repeated at least 3 times. All the results were expressed relative to WT expression considered as 100%.
In situ hybridization
In situ hybridization histochemistry was performed following a previously described protocol (38) with adjustments described below. Animals were anesthetized and perfused intracardially following protocol with 10% phosphate-buffered formalin (Fisher Scientific). Brains were removed to a 10% sucrose solution in 10% phosphate-buffered formalin overnight at 4ºC with gentle shaking to be sectioned the next day. Coronal sections 30 µm thick were cut using a Leica SM 2000R sliding microtome (Leica Microsystems, Bannockburn, Illinois, USA). Sections were collected free-floating in cold phosphate buffered saline (PBS) treated with DEPC and mounted as previously described onto Fisher Scientific Superfrost Plus slides (38) . After drying, slides were treated with a 0.001% proteinase K solution. Hybridization was carried out overnight (16-18 hours) at 65ºC on a slide warmer using 1 x 10 7 cpm of probe per ml of hybridization solution prepared as per protocol.
To prepare the riboprobe used in hybridization, bases 272 to 629 of exon 3 of the mouse thyrotropin releasing hormone gene (NCBI, accession# NM_009426) was PCR amplified from WT mouse genomic DNA using the forward primer, 5'-TCCTG G A T C C C A A A A C G CCAGCAT-3', with the change of a single base to create an internal Bam HI site. The reverse p r i m e r ,
' -A G C T T C T T T G G A G C T CAGGATCTA-3'
, contained an internal SacI site. The PCR product was ligated into pGEMT (Promega Corp.) and sequenced. To linearize the vector for in vitro transcription, 5 µg of DNA was digested with SalI and phenol/chloroform extracted. Transcription was completed using 1 µg of DNA template, with the Promega Riboprobe in vitro Transcription System, which included 35 S-UTP. Post-hybridization washes and film signal detection of sections followed protocol with exposure of slides for 3 days to Kodak BioMax-MR film (Eastman Kodak Co.). Slides were then coated with NTB emulsion (Eastman Kodak) and protected from light in an aluminum foil-covered microscope slide box at 4°C for 3 weeks. Images of sections after development were captured and quantitated using the software Image Pro Plus, version 4.5.1.22 for Windows (Media Cybernetics, Inc., Silver Spring), and an Olympus BH2-RFCA microscope (Olympus America Inc.) equipped with a Sony DXC-960MD color analog video camera (Sony Corp). After subtracting background measurements, the mean values for the PVN and for the lateral hypothalamus of each animal were calculated. The TRH expression within PVN is regulated by T 3 (39) (40) (41) . Ratios were then calculated of the mean PVN value to the mean lateral hypothalamic (area not affected by T 3 ) value for each animal to determine the relative degree of difference in TRH mRNA expression of the TRH-regulated PVN relative to the lateral hypothalamus.
Immunohistochemistry
Animals were anesthetized and then perfused intracardially with 4% paraformaldehyde. Pituitaries were excised and post-fixed overnight at 4ºC with 4% paraformaldehyde containing 10% sucrose and gently shaken. Tissues were embedded in paraffin and sectioned in 3µm thick slices sagittally. Sections were prepared and blocked with 2% normal goat serum (Vector Labs) for 1 hour at room temperature and hybridized with a 1:1000 dilution of rabbit anti-rat TSH-β antibody obtained from Dr. A.F. Parlow of the National Hormone & Peptide Program (rTSH-β-IC-1, lot# AFP1274789) overnight (16-18 hours) at 4ºC. After sections were washed and biotinylated goat, anti-rabbit secondary antibody (Vector Labs) applied for 1 hour at room temperature, sections were washed. Avidin-biotinhorseradish peroxidase, provided in the Standard Elite Vectastain ABC kit (Vector Labs), was applied according to standard protocol. Sections were DAB stained with nickel enhancement or DAB (Vector Labs) and hematoxylin to visualize TSH positive cells, or thyrotrophs, for the purpose of counting cell number. Three non-overlapping areas in the anterior pituitary of 3 to 5 animals per group were observed under 400x magnification and the images captured (Image Pro Plus). The total number of cells and the number of TSH-β positively stained cells were counted for the entire field-of-view of each area. To determine the relative amount of TSH-β immunopositive cells, the ratio of the number of TSH-positively-stained cells to the total number of cells for each field-of-view was calculated.
Histology
Thyroid glands were excised, washed once with PBS, and then fixed in 10% phosphatebuffered formalin and embedded in paraffin. Sections 6 µm thick were prepared and stained with hematoxylin/eosin (H&E).
Statistical analysis
Data are reported as means ± SEM. Oneway ANOVA followed by Student-NewmanKeuls multiple comparisons test was employed for assessment of significance when comparisons were made within the same genotype. Two-way ANOVA was employed when mice of different genotypes and treatment were compared (GraphPad Prism, GraphPad Software, Inc.).
All experiments were repeated at least 3 times, except the experiment with TRH treatment that was repeated twice.
RESULTS
To compare the relative importance of TRH and TRβ in feedback regulation of the HPT axis, we generated three groups of KO mice each deficient in either or both protein(s). To establish that double KO mice were not expressing TRH, we measured hypothalamic TRH mRNA using in situ hybridization histochemistry ( Figure 1A) . As expected, TRH mRNA was absent in TRH KO and double KO mice, while TRβ KO mice demonstrated an increase in the TRH expression in the paraventricular nucleus (PVN) when compared to WT animals ( Figure 1B) . The latter result is consistent with a defect in negative T 3 regulation of the TRH neuron as reported previously (20) . Double KO mice were born with no gross anatomic or functional abnormalities and were viable through adulthood. Both male and female mice displayed normal fertility.
As previously reported, the absence of TRβ results in a defect in negative feedback regulation of the HPT axis resulting in higher TH levels in these mice. As shown in Figure 2 , total serum T 3 and T 4 levels were highest in the TRβ KO mice, reaching statistical significance versus WT mice (15, 16, 27) . Consistent with previous reports, TRH KO mice presented with decreased serum T 4 levels when compared to WT animals (P<0.001). Interestingly, double KO mice displayed reduced T 4 levels similar to that observed in TRH KO mice (P<0.001, Figure  2 ). Serum T 3 levels in both TRHKO and double KO were similar to WT mice, perhaps reflecting an increase in serum 5' deiodinase activity in these animals. We also measured TH levels in animals with heterozygous genotypes generated from our breeding strategy (data not shown). TRH haploinsufficiency alone or combined with homozygous TRβ deletion was insufficient to change basal thyroid hormone levels compared to WT and TRβ KO animals, respectively. Furthermore, TRβ haploinsufficiency alone or combined with homozygous TRH deletion was insufficient to change basal thyroid hormone levels compared to WT and TRH KO animals, respectively.
Therefore we excluded these heterozygous genotypes from further study.
As expected, TRβ KO animals showed resistance to TH and presented with elevated serum TSH levels (an 8-fold increase) when compared to all other groups (P<0.001, Figure 2 ). TRH KO mice and double KO, in contrast, had only a threefold increase in serum TSH levels compared to WT animals. Since TRb was deleted in three of the four genotypes, we wanted to confirm that expression of the remaining TRa1 isoform was not altered in these animals. We found no significant differences in TRα1 mRNA levels in the pituitary of all genotypes studied (data not shown).
To determine serum TSH bioactivity in these animals, an in vitro cAMP assay was utilized. Figure 3A (upper panel) demonstrates that serum from all three KO genotypes increased cAMP levels in this assay when compared to WT mice. T S H bioactivity (middle panel) was then determined by correcting for serum TSH levels (cAMP/TSH ratio). After this correction, TSH bioactivity was decreased in all KO groups when compared to the WT mice, being significantly decreased in TRH and double KO mice. Another measure of TSH bioactivity is the serum T 4 /TSH ratio (ref. 28 and Refetoff S., unpublished results). The T 4 /TSH ratio ( Figure 3A , lower panel) of all KO groups showed a significantly decreased ratio compared to WT animals. This assay, however, underestimates TSH bioactivity when TSH values are markedly elevated due to the linear-log relationship between changes in T 4 and TSH. A third measure of TSH bioactivity is a histological assessment of thyroid gland size ( Figure 3B) . Thyroid glands were smaller in TRH and double KO mice ( Figure 3C , lower panel), consistent with a decrease in TSH bioactivity (based on two assays) in these mice versus WT mice. I n contrast, these animals were of normal body weight ( Figure 3C , upper panel). Due to the younger age of our animals, we did not observe an increase in thyroid gland size in TRβ KO mice, which is typically found after 6 months of age.
To investigate further the regulation of the HPT axis in these animals, all four groups were examined in both a thyroid hormone-deficient and an excess state. After 35 days of a Lo I/PTU diet supplemented with MMI in the water, all mice, except the double KO animals, presented with undetectable T 4 levels (data not shown) and markedly elevated TSH levels (>10,000mU/l, Figure 4A ). In the double KO group, serum T 4 levels were undetectable but serum TSH levels did not increase as much during hypothyroidism (< 10% of hypothyroid WT levels, Figure 4A and 4B). L-T 3 treatment was then administered by daily subcutaneous injections at three different concentrations. At the end of the low dose period, serum TSH decreased in all groups but the decline was more marked in the TRH KO mice. After the highest L-T 3 dose, all groups had serum T 3 levels of approximately 200 ng/dl, with no significant differences among the groups (data not shown). Serum TSH levels, however, were statistically significantly lower in the WT and TRH KO mice versus TRβ and double KO mice ( Figure 4A,  inset) . Thus, L-T 3 treatment reduced serum TSH in every group, but both the double KO mice and as reported previously, the TRβ KO mice demonstrated a resistance to L-T 3 suppression at the highest dose (2, 27) .
Like serum TSH, TSH subunit mRNA levels in double KO mice were not significantly elevated after PTU treatment ( Figure 4C and 4D) . TSH α and β subunits mRNA responded to PTU treatment in all groups (except double KO animals). However, the magnitude of TSH-α subunit mRNA response was lower when compared to the TSH-β subunit mRNA levels ( Figure 4C and 4D, respectively) .
To define the number of TSH-producing cells in the pituitary, TSH-β immunopositive cells were quantitated in all groups after induction of hypothyroidism ( Figure 5 ). After 35 days of LoI/PTU + MMI treatment, the number of TSH-β immunopositive cells, corrected for total cells in the field, was similar in WT and TRβ KO mice ( Figure  5B , lower panel). In contrast, the number of TSH-β immunopositive cells was somewhat lower in TRH KO mice and significantly lower in the double KO mice. Fewer TSH-β immunopositive cells were observed throughout the anterior lobe of the double KO animals (P<0.01) when compared to WT mice, correlating with measurements of serum TSH levels at the end of the hypothyroid period ( Figure 5C ).
We next evaluated pituitary TSH-β immunostaining in hypothyroid animals after 10 days of treatment with a slow-release TRH or placebo pellet ( Figure 6 ). After LoI/PTU + placebo treatment for 3 weeks, pituitary TSH-β immunostaining ( Figure 6A ) and serum TSH levels (data not shown) were similar to the results showed in Figure 5 for WT and double KO mice. After TRH treatment, the number of detectable TSH-β immunopositive cells significantly increased in double KO animals and was not different from WT animals ( Figures 6A and 6B) or TRH KO and TRβ KO mice (data not shown). Importantly, serum TSH levels were also similar after TRH treatment (TSH WT: 2943±2427, TRβ KO: 3709±2654, TRH KO: 3045±1693, DKO: 2923±630 mU/L).
DISCUSSION
The physiological set point for TSH synthesis and release is determined by a balance between a positive input from hypothalamic TRH and a strong negative influence by thyroid hormone. Together these opposing influences determine the amount of TSH synthesized and secreted. It has also been demonstrated in TR KO animals that TRβ2 is the dominant isoform mediating T 3 -negative regulation of TSH subunit gene expression in the pituitary and that TRβ 2 is the main isoform regulating TRH gene expression in the hypothalamus (16, 20) . The importance of TRβ2 in regulating the HPT axis may reflect a higher expression level of this isoform in tissues regulating the HPT axis, since it has been shown that somatic gene transfer of either TRβ1 or TRβ2 rescues the hypothalamic defect in TRH negative regulation in TRβ KO animals (29) . In contrast, TRα1 deletion alone or in combination with α2 causes a mild central hypothyroidism perhaps due to a regulatory or developmental defect in the HPT axis (13, 14, 30) .
Hypothyroidism is necessary but not sufficient to upregulate the HPT axis. This was suggested by a study of patients with central hypothyroidism caused by hypothalamic dysfunction and definitively shown in mice lacking TRH (26, 31) .
Hypothalamic TRH deficiency in humans and rodents has been shown to decrease TSH bioactivity by changing its glycosylation pattern (31, 32) . In humans and rodents lacking TRH, decreased TSH bioactivity was demonstrated by an increase in serum TSH levels relative to WT animals associated with a reduction in serum T 4 levels. The reduction in TH levels and change in TSH glycosylation were then corrected after exogenous administration of TRH to TRH deficient animals (26, 31) . In addition to an effect on TSH bioactivity, TRH deficiency is also thought to reduce the number of pituitary thyrotrophs in adult mice (25) .
The relative importance, however, of these positive and negative inputs in the central axis has yet to be determined in vivo. By deleting either TRβ, TRH or both in mice, we sought to address this question. As previously reported, TRβ KO animals demonstrated significant increases in TH and TSH levels at 16 weeks of age, confirming resistance to TH. Also as reported, TRH KO mice have reduced T 4 levels associated with a 2-3-fold increase in serum TSH levels. Interestingly, double KO mice were indistinguishable from TRH KO animals.
Our data in TRH and double KO mice demonstrate lower serum T 4 levels associated with higher serum TSH values, suggesting a decrease in the TSH bioactivity. TSH bioactivity was measured directly by determining cAMP generation in an in vitro TSH bioassay. Although serum TSH levels were higher in all KO groups, cAMP/TSH ratios (a measure of TSH bioactivity) were decreased when compared to WT animals ( Figure 3A) . This finding most likely illustrates the critical role that TRH plays in TSH glycosylation in the anterior pituitary, as previously reported (31-33). We did not observe a goiter TRβ KO animals even though their absolute TSH level was elevated ( Figure 3B and C) . This may be due to the age of the mice used in our study -we find that goiter in TRβ KO animals is agedependent. In contrast, the thyroid gland was smaller in TRH and double KO mice, suggesting that the increased serum TSH levels in these mice could not compensate for a reduction in serum TSH bioactivity.
We next studied negative regulation of the central axis by T 3 after animals were rendered hypothyroid. As previously reported (27) , TRβ KO animals were less responsive to T 3 such that at the highest T 3 dose TSH was still markedly elevated ( Figure 4A, inset) . Double KO mice behaved as TRβ KO animals even though TSH levels were much lower at the beginning of T 3 -treatment (see below). In contrast, the responsiveness of the thyrotroph to exogenous T 3 was increased in TRH KO mice; TSH values returned rapidly with the smallest T 3 dose. This result suggested that the thyrotroph might be more sensitive to T 3 negative feedback without hypothalamic TRH input. The most unexpected result in this study was that thyrotrophs from double KO mice failed to respond to hypothyroidism. This experiment was designed to ensure that all the groups became equally hypothyroid before administration of T 3 (T 4 was undetectable in all groups treated with LoI/PTU and MMI). Serum TSH levels were at least 50-fold lower, and TSH subunits mRNA levels at least 2-fold lower, in double KO mice during the hypothyroid phase of the experiment. Given that we observed appropriately increased serum TSH levels in WT, TRH KO and TRβ KO mice, we concluded that the presence of both TRβ and TRH is necessary for a normal thyrotroph response during hypothyroidism suggesting that unliganded TRβ stimulates TSH subunit gene expression (Figure 4) .
Support for these findings can be found in previous studies of primary thyrotroph cell cultures, which demonstrated that either TRH or the absence of TH was sufficient to mediate an increase in TSH subunit gene transcription (2, 34) .
To explore further the mechanism for the decreased serum TSH in double KO mice, we measured the number of TSH-β immunopositive cells in pituitary sections. Compared to WT animals, the number of TSH-β immunopositive cells was similar in TRβ KO mice, somewhat decreased (but not significantly) in TRH KO mice, and markedly decreased in double KO animals during hypothyroidism. Since the number of detectable TSH-β immunopositive cells was decreased in the double KO during induced hypothyroidism ( Figure 5A, B) , these data could suggest that the combination of TRH and TH (via TRβ) are required for thyrotroph cell development and/or maintenance.
To confirm this hypothesis, we evaluated the response of KO animals to TRH stimulation ( Figure 6 ). Slow-release TRH or placebo pellets were implanted in hypothyroid animals. After this treatment, no significant differences in either TSH-β immunopositive cells or serum TSH levels were found among the groups, indicating that the defect in double KO mice was corrected after TRH treatment. These results indicate that the decreased serum TSH values observed in the double KO animals during hypothyroidism are due to decreased TSH synthesis and not due to a reduction in thyrotroph cell number.
Others have shown that TRH is not physiologically required for the proliferation or differentiation of embryonic thyrotrophs. After birth, however, the number of TSH-β immunopositive cells decreases showing the importance of TRH in maintenance of normal postnatal functions of the pituitary thyrotrophs (25) . Our results show that TRH KO mice respond normally or nearly normally to hypothyroidism but that double KO mice display a significantly impaired response. Serum TSH both failed to increase normally after hypothyroidism as well as suppress normally after T 3 administration. These data suggest a previously unrecognized interaction between TRH and TH signaling pathways in mediating the hypothyroid TSH response. We can also speculate that TRH signaling may enhance stimulation by the unliganded TRβ by an unknown cross-talk mechanism.
In conclusion, TRH is critical for normal regulation of the HPT axis. TRH absence causes central hypothyroidism in mice due to the synthesis of biologically less active TSH. When challenged with primary hypothyroidism, however, the central axis is also unable to respond normally in mice lacking TRH, even when negative feedback is also disrupted (double KO mice). This defect in double KO mice reflects a marked decrease in TSH synthesis, which was reversed by chronic TRH stimulation. Although hypothyroidism is known to markedly increase TSH synthesis at a transcriptional level, these results indicate an unexpected, dominant role for TRH in regulating the HPT axis in the basal and hypothyroid state.
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